Skip to content
PIL Logo

AUBAGIO 14 mg film-coated tablets

Last Updated on eMC 09-Nov-2017 View document  | Genzyme Therapeutics Contact details

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC.  For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 09-Nov-2017 and displayed until Current

Reasons for adding or updating:

  • Change to section 6 - date of revision
  • Change to other sources of information section

Updated on 31-Jul-2017 and displayed until 09-Nov-2017

Reasons for adding or updating:

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 6 - date of revision

Updated on 28-Jun-2017 and displayed until 31-Jul-2017

Reasons for adding or updating:

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 2 - driving and using machines
  • Change to section 2 - use in children/adolescents
  • Change to section 2 - excipient warnings

Updated on 17-May-2017 and displayed until 28-Jun-2017

Reasons for adding or updating:

  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect

Updated on 28-Apr-2017 and displayed until 17-May-2017

Reasons for adding or updating:

  • Change to section 2 - driving and using machines
  • Change to section 2 - excipient warnings
  • Change to section 3 - dose and frequency
  • Change to section 3 - use in children/adolescents
  • Change to section 3 - how to take/use
  • Change to section 3 - duration of treatment
  • Change to section 3 - overdose, missed or forgotten doses
  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect

Updated on 09-Dec-2015 and displayed until 28-Apr-2017

Reasons for adding or updating:

  • Change to section 4 - possible side effects

Updated on 08-Jul-2015 and displayed until 09-Dec-2015

Reasons for adding or updating:

  • Change to section 4 - possible side effects

Updated on 07-Oct-2014 and displayed until 08-Jul-2015

Reasons for adding or updating:

  • Change to section 4 - possible side effects
  • Change to other sources of information section

Updated on 16-Jan-2014 and displayed until 07-Oct-2014

Reasons for adding or updating:

  • New PIL for new product

Company contact details

Genzyme Therapeutics

Company image
Address

4620 Kingsgate, Cascade Way, Oxford Business Park South, Oxford, Oxfordshire, OX4 2SU

Fax

+44 (0)1865 774 172

Medical Information e-mail
Medical Information Fax

+44 (0)1865 774 172

Telephone

+44 (0)1865 405 200

Medical Information Direct Line

+44 (0)1865 405 283

Customer Care direct line

+44 (0)1865 405 200

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

teriflunomide

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue